PI-103 | CAS No. 371935-74-9

PI-103

Basic Information

View in Editor

CAS Number

371935-74-9

Molecular Formula

C19H16N4O3

Molecular Weight

348.36 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Ethers

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Basic Physical Properties

Boiling Point

520.25°C at 760 mmHg

SMILES

View in Editor

C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O

InChI

InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2

InChIKey

TUVCWJQQGGETHL-UHFFFAOYSA-N

LogP

2.980200000000001

Topological Polar Surface Area

84.51 Å²

Hydrogen Bond Donor/Acceptor

1 / 7

Complexity

489

Safety Information

View Safety Information

Hazard Statement

H302 Harmful if swallowed
Acute toxicity, oral

H315 Causes skin irritation
Skin corrosion/irritation

H319 Causes serious eye irritation
Serious eye damage/eye irritation

Synonyms & References

English

AC-31514
3-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol
NCGC00187906-01
HMS3244E12
BCPP000107
Kinome_3597
HMS3229C15
3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol
PI 103
SR-01000946304-1
Q27088379
NSC-759676
TUVCWJQQGGETHL-UHFFFAOYSA-N
YQX02F616F
2x6k
UNII-YQX02F616F
SMR002530603
mTOR Inhibitor, PI103
BCP19373
pyridofuropyrimidine derivative, 2
NCGC00187906-03
371935-74-9
3-[4-(4-Morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol
3-(4-morpholin-4-ylpyrido[3 ,2 :4,5]furo[3,2-d]pyrimidin-2-yl)phenol
HMS3654E09
NSC776996
PI103
compound 2 [PMID: 17601739]
SCHEMBL258242
AMY23717
3-(4-(4-morpholinyl)pyrido[3?,2?:4,5]furo[3,2-d]pyrimidin-2- yl)phenol

MDL Number

MFCD11983145

FAQ

What regulatory guidelines apply to PI-103 (CAS: 371935-74-9)?

PI-103 (CAS: 371935-74-9) must comply with REACH regulations in the European Union, ensuring that it meets the criteria for classification, labeling, and packaging. In the United States, it adheres to the FDA's Good Manufacturing Practice (GMP) guidelines and EPA's Resource Conservation and Recovery Act (RCRA) for waste management. Additionally, it should follow GHS (Globally Harmonized System of Classification and Labelling of Chemicals) for hazard communication and safety data sheets (SDS).

Are there alternatives to PI-103 (CAS: 371935-74-9) in synthesis?

While PI-103 (CAS: 371935-74-9) is a potent inhibitor, alternatives such as PI-103 analogs and isomers like PI-105 and PI-106 have been explored. Common alternative reagents for synthesis include various amines and carboxylic acids. These provide similar functionalities but may offer different reactivity and solubility profiles, making them suitable for specific applications.

What is the market or research trend for PI-103 (CAS: 371935-74-9)?

The market for PI-103 (CAS: 371935-74-9) is growing due to its role as an inhibitor in various biological processes. Research trends indicate a focus on its application in cancer therapy and as a therapeutic agent. Market projections show increasing demand, driven by advancements in drug delivery systems and the need for targeted cancer treatments. However, price trends vary depending on supply and demand factors in the pharmaceutical industry.

How should waste containing PI-103 (CAS: 371935-74-9) be handled?

Waste containing PI-103 (CAS: 371935-74-9) should be collected in appropriate containers and labeled with the proper hazardous waste symbol. For disposal, it is recommended to incinerate the waste under controlled conditions or use professional waste disposal services. Ensure all safety precautions are followed, including proper ventilation and personal protective equipment (PPE). Environmental protection measures include minimizing exposure and adhering to local and international waste disposal regulations.